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When used as scaffolds for cell therapies, biomaterials often present basic handling and 
logistical problems for scientists and surgeons alike. The quest for an appropriate mounting 
device for biomaterials is therefore a significant and common problem. In this review we 
provide a detailed overview of the factors to consider when choosing an appropriate mounting 
device including those experienced during cell culture, quality assurance and surgery. By way 
of example, we draw upon our combined experience in developing epithelial cell therapies for 
the treatment of eye diseases. We discuss commercially available options for achieving 
required goals and provide a detailed analysis of four experimental designs developed within 
our respective laboratories within Australia, the United Kingdom and Belgium. 
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The fields of biomaterials and regenerative medicine (incorporating stem cells and tissue 
engineering) have developed in a complimentary manner over the last twenty years. This 
research nexus is particularly well demonstrated by the growing exploration of biomaterials as 
vehicles for cell implantation 1. Given the breadth of materials and cell types currently under 
investigation, we have presently chosen to focus on examples drawn from the field of 
ophthalmology. In doing so, however, we provide a comprehensive discussion of the 
problems and their potential solutions that we consider will be common to many other 
surgical fields. More specifically, this paper examines the critical issue of how biomaterials 
should be mounted in preparation for cell culture and implantation.  
 
When designing a cell therapy, the emphasis is generally initially placed on optimizing the 
culture medium ingredients required to maximize cell yield and purity 2,3. During these 
preliminary studies it is likely that the experimental cultures are grown on commercially 
available tissue culture plastics including polystyrene. Tissue culture plastic is nonetheless 
unsuitable for implantation into the body and so the research team must eventually translate 
their findings to a more biocompatible substrate. During this translation phase, however, a 
number of key substrate properties are likely to be altered in ways known to affect the 
structure and/or function of the bioengineered tissue including substrate rigidity 4 and surface 
topography (i.e. two-dimensional versus three-dimensional)5. Depending upon how 
biomaterials are mounted, it may well be possible to optimize these characteristics by 
applying varying amounts of tension to promote substrate flattening and stretching if required. 
  
It may also be advantageous in some cases to mount cultures in a way that supports 
independent feeding and monitoring of the apical and basal culture surfaces. Moreover, the 
ability to visualize cell cultures using non-invasive techniques (e.g. phase contrast 
microscopy) throughout manufacture is highly beneficial for quality assurance purposes. We 
presently demonstrate how these considerations have been incorporated into methods for 
mounting biomaterials used in ocular cell therapies.  
 
 
2. Overview of ocular cell therapies 
 
Three principal areas of current research focus for ocular cell therapies include the ocular 
surface, the corneal endothelium (i.e. posterior surface of the cornea) and the retinal pigment 
epithelium. The common goal in each case is essentially to restore structure and function to an 
epithelial tissue. The technical requirements for establishing and validating each epithelial cell 
function prior to implantation, however, vary considerably between each cell type. These 
differences are reflected in the choice of techniques for mounting biomaterials used during 
cell culture and implantation.  
 
2.1. Cell therapies for ocular surface reconstruction. The ocular surface is comprised of two 
distinctly different cell types. The corneal epithelium forms the smooth, transparent corneal 
surface, and the conjunctival epithelium covers the adjacent sclera and inner lining of the 
eyelids. Since both epithelia are essential for maintenance of a healthy ocular surface, 
techniques have been developed for treating diseases of the ocular surface using cultivated 
  
sheets of corneal epithelial cells and conjunctival epithelial cells 6-8. In the case of the corneal 
epithelium, the necessary progenitor cells are isolated from the peripheral margin or so called 
corneal limbus 9. Progenitor cells for the conjunctival epithelium are typically isolated from 
the inferior fornix, where the conjunctiva extends onto the inner lining of the lower eyelid 10. 
Assessment of culture quality in both cases is essentially limited to confirmation of cell 
phenotype using microscopy and immunocytochemistry. While both epithelial tissues display 
stratification in vivo, this is not generally considered essential for culture efficacy following 
implantation.  
 
In most cases, the cultivated corneal and conjunctival epithelial cells have been implanted 
while attached to sheets of human amniotic membrane (HAM) 11,12. Standard techniques for 
processing HAM involve flattening onto nitrocellulose backing membrane and cutting into 
discs, before being stored frozen in 50% glycerol. Once thawed, the dead remnants of 
amniotic epithelial cells are usually removed using enzymatic digestion prior to seeding of 
epithelial cells. Considerable care is required throughout these processes in order to prevent 
the HAM from becoming detached from the backing paper. Once detached, the HAM readily 
becomes crumpled when immersed in liquid. Leaving the backing paper on, however, 
prevents monitoring of cultures by phase contrast microscopy. The ideal solution is therefore 
to mount freestanding sheets of denuded HAM within some form of supporting frame that 
keeps the material taut and flat during culture and subsequent application to the ocular 
surface. Similar considerations would also apply using alternatives to HAM such as fibrin 
glue 13,14. Notably others have reported successful clinical outcomes using contact lenses as a 
substrate for epithelial cells during their cultivation and implantation 15,16. Moreover, others 
  
have avoided use of a substrate during implantation via use of temperature-responsive culture 
plastic that supports release of a freestanding sheet 17. In the absence of a standardized 
procedure, however, a variety of experimental substrata including membranes derived from 
silk proteins 18,19 are being explored, each with inherent differences in their physical and 
mechanical properties that can complicate handling during cell culture and surgery. 
 
2.2. Cell therapies for repairing the corneal endothelium. The corneal endothelium is a 
monolayer of epithelial cells that resides on the posterior surface of the cornea. Corneal 
transparency is dependent on Na+/K+ ATPase enzyme activity that resides in the basal lateral 
surface of corneal endothelial cells. Through regulating the movement of ions between the 
corneal stroma and anterior chamber of the eye, there is a corresponding movement of water 
that in turn facilitates the correct spacing of extracellular matrix components required for 
corneal transparency. Any reduction in corneal endothelial cell density through disease or 
trauma therefore leads to corneal opacity that can only be rectified via the replacement of lost 
cells.  
 
Traditionally, corneal endothelial cells are replaced by performing a donor corneal transplant. 
Owing to the relative immune privilege of the cornea, the majority of corneal transplants last 
approximately 10 years prior to failure 20. In an effort to extend graft survival time, surgeons 
have developed a more refined implantation technique where only the most posterior portion 
of the cornea is implanted using keyhole surgery 21. This technique involves implanting the 
donor endothelium while attached to Descemet’s membrane – a thickened basement 
membrane that separates the endothelium from the posterior corneal stroma. The reliance 
  
upon use of donor tissue, however, has prompted researchers to investigate the feasibility of 
implanting corneal endothelial cells that have been cultivated on some form of prosthetic 
Descemet’s membrane 22,23. Since the adult corneal endothelium displays limited proliferative 
capacity, various other progenitor cell types are being considered as an alternative cell source 
including mesenchymal stromal cells 24 and induced pluripotent stem (iPS) cells 25.  
 
Potential substrata for growing corneal endothelial cells include de-cellularized human 
corneal tissue 26,27, lens capsules 28, sheets of collagen type I  29,30, gelatin hydrogels coated 
with collagen type IV 31, chitosan-based membranes  32,33, biodegradable polymer membranes 
34, PEG-based hydrogel films  35 and hydrogel contact lenses 36. Generally, these materials 
have been tested with minimal support by simple placement in culture dishes. One group has 
generated sheets of corneal endothelial cells after growth on temperature responsive surfaces 
37. In this case, discs of gelatin hydrogel were attached to the apical surfaces of the corneal 
endothelial cell sheets for handling and transport 37.  
 
Examples of materials that have been used in combination with a support structure inside the 
tissue culture dish to grow corneal endothelial cells are HAM and collagen type I. These 
materials have been placed on either commercially available tissue culture inserts 38 or on 
slim nylon or Teflon™ rings on the bottoms of tissue culture wells 39-41. Corneal endothelial 
cells can also be grown on membranes of silk fibroin that have been coated with collagen type 
IV 22 and mounted within Teflon™ chambers (refer to section 4.1.3).  
 
  
Sheets of corneal endothelium that have been grown in the laboratory are commonly tested 
for the presence of key proteins that are required for corneal endothelium function by 
immunocytochemistry. These proteins include zonular occludens-1 (ZO-1), an indicator of 
barrier function, and Na+/K+-ATPase, an indicator of ion transport. To check for Na+/K+-
ATPase activity, cell sheets can be tested for their ability to generate ion flow in an Ussing 
chamber. For this analysis, the cell sheets, supported by their carrier materials, are suspended 
vertically between two chambers, and short circuit current and transendothelial resistance 
values are recorded. Data from these analyses provide an indication of the cells potential 
ability to pump water through the mechanism of electro-osmosis 42. While a limited number 
of research centers have reported success by injecting suspensions of corneal endothelial cells 
into the anterior chamber of the eye 43,44, the majority of efforts are focused on implanting a 
functioning sheet. 
 
2.3. Cell therapies for restoring the retinal pigment epithelium. The retinal pigment 
epithelium (RPE) is a monolayer of epithelial cells that separates the photoreceptor layer of 
the retina from the vascularized choroidal tunic of the eye. While performing a range of 
barrier and transport functions typical of other epithelia, the RPE is essential for the function 
and survival of adjacent photoreceptor cells 45. RPE cells also share properties with white 
blood cells since they are engaged in phagocytosis of photoreceptor outer segments shed daily 
from the tips of adjacent rods and cones. In addition, RPE cells facilitate maintenance of a 
healthy blood supply through the balanced release of pro-angiogenic and anti-angiogenic 
growth factors from their basal and apical surface respectively.  
  
There is presently wide interest in developing cellular therapies based upon the implantation 
of cultured RPE owing to the increasing prevalence of age-related macular degeneration 
(AMD) 46. Two main forms of AMD have been indentified. In so-called “wet-AMD” the 
degeneration of RPE cells and adjacent photoreceptors is accompanied by ectopic growth of 
leaky blood vessels into the sub-retinal space. Whereas the “dry” form of AMD is limited to 
localized or geographic atrophy of the RPE and adjacent photoreceptor cells. In wet AMD, 
the growth of blood vessels beyond the choroid is facilitated by disruption to Bruch’s 
membrane, a thin layer of extracellular matrix components contiguous with the basement 
membranes of the RPE and adjacent capillary layer of the choroid (choriocapillaris). 
Strategies for reconstructing both Bruch’s membrane as well as the RPE may therefore be 
equally important for the treatment of AMD patients.  
 
While it is possible to generate cultures of RPE cells from adult donor eye tissue 47, the 
resulting cultures can vary greatly due to a number of factors (e.g. age of donor tissue, 
availability of tissue within a certain timeframe after death, and the presence of retinal 
disease). Current strategies for RPE cell therapy are therefore predominantly focused on the 
creation of RPE cells from pluripotent stem cells, including embryonic stem cell (ES) and 
induced (adult) stem cell (iPS) sources. A number of clinical trials have been working with 
autologous iPS-RPE cells derived from individual patients as a type of personalized medicine 
48. However, due to the cost and timescale of production, if a cellular therapy was to be 
available on a large scale, the utilization of cell banking will likely be the future of iPS 
technology 49,50. This will ideally involve matching the human leukocyte antigen (HLA) type 
between donor and patient. This is a routine procedure with most organ transplants. Banking 
  
multiple HLA types will increase the availability of the therapy option and avoid immune 
rejection of the donor cells by the patient’s immune system. This approach has been trialed 
using human RPE cells derived from donor retinal tissue51, and more recently using primate 
RPE cells derived from donor iPS cells50. 
 
A biomaterial membrane that could be used as a substitute for Bruch’s membrane would 
ideally also serve as a cell carrier during transplantation, and act as a template to guide 
reconstruction of the sub-retinal architecture. This poses several issues with how to handle the 
biomaterial during cell culture and then during surgery. Out of the multitude of studies that 
have evaluated potential substitutes for Bruch’s membrane (comprehensively tabulated by Jha 
and Bharti, 2015)52, only a few have progressed towards pre-clinical and clinical studies. One 
of these biomaterials, a permeable polyester substrate (Clinical Trial #NCT01691261) 53 has 
been reportedly transplanted into a human patient; however the trial is currently suspended. 
 
The cultured RPE monolayer on an appropriate Bruch’s membrane substitute will most likely 
need to be fully functional prior to implantation in order to achieve best clinical outcomes. A 
number of functional tests have therefore been developed to test RPE cultures in vitro. 
Electron microscopy can be used to confirm the correct morphology of RPE monolayers at 
the ultra-structural level including the formation of dense apical microvilli and tight junction 
complexes between neighboring cells. The culture should be pigmented with melanin 
granules polarized to the apical cytoplasm. The basal surface of the cells should show 
membrane in-foldings with native extracellular matrix deposition evident along the cell-
biomaterial interface. The trans-epithelial resistance of cultures can be measured over time as 
  
a way to study the development of barrier function and this test has been used as a sign of 
readiness for further functional testing, and implantation studies. The expression of important 
RPE proteins can be localized using immunocytochemistry to demonstrate polarization and 
indicate functionality. These proteins include bestrophin, claudin-19, cellular retinaldehyde 
binding protein (CRALBP), cytokeratin 8/18, ezrin, Na+/K+-ATPase, RPE-65, and ZO-1. The 
polarized secretion of growth factors can be quantified using proteomic analysis of 
conditioned apical and basal culture media by immunoassay. Finally, the phagocytosis of 
fluorescently labeled extracellular particles (e.g. labeled photoreceptor outer segments or 
synthetic surrogates) is often used as a critical measure of RPE function. This test can be 
quantified using laser scanning confocal microscopy as well as flow cytometry. More 
recently, the National Eye Institute, USA has developed a comprehensive suite of 
physiologically relevant tests to analyze the ATP-mediated, purinergic signaling pathway 
within their iPS-RPE cell cultures 54. This pathway is critical for controlling the composition 




3. Current options for mounting of biomaterials 
 
3.1. Strategies used by developers of technology. The first option to consider when working 
with a biomaterial is to simply place the material flat in the bottom of a standard cell culture 
dish or suspended within a hanging porous cell culture insert (e.g. Transwell® cell culture 
insert) 55,56. This approach is particularly well suited to more rigid materials such as scaffolds 
  
prepared from synthetic polymers. In the case of buoyancy, some form of ring-shaped weight 
can be applied to maintain submersion in culture medium. Silicone rubber O-rings are 
particularly useful as weights since they are inexpensive and can be readily sterilized via 
multiple methods including use of an autoclave. The O-ring size can also be selected to fit 
snugly to the inner wall of culture wells thus helping to prevent floating of biomaterials. 
Nevertheless, the use of less rigid materials including HAM and fibrin glue has led to a 
variety of strategies being developed. 
 
In the case of HAM a number of initial studies described placing this material flat in the 
bottom of either a conventional culture dish 57,58 or within a cell culture well insert 59. 
Alternatively, the HAM was draped across a platform of stainless steel mesh with a large 
central hole to facilitate visualization of the cultures 7,60. Cell culture inserts subsequently 
emerged as the preferred support platform for HAM since this culture system supports use of 
techniques designed to optimize epithelial cell culture: namely cultivation at the air-liquid 
interface and use of mesenchymal cell feeder layers 61-63. In later studies, HAM was secured 
to the base of cell culture inserts, with or without removal of the porous membrane base 62,63. 
Tethering of HAM was presumably performed for the purpose of flattening the membrane 
and thus achieving a more even confluency of cells. These authors may also have intended to 
improve cell growth on HAM by increasing substrate tension, but this goal to the best of our 
knowledge has never been stated. More recently, others have mounted sheets of HAM within 
a frame constructed from two interlocking rings constructed from stainless steel 64. This 
simple and effective design is similar in concept to that developed independently by two of 
our own groups that we will discuss later (sections 4.2 and 4.4). 
  
 
While fewer researchers have utilized fibrin glue as a substrate for ocular cells, this material 
has been routinely adopted by at least one center, based upon many years of research by one 
of the field’s pioneers, Graziella Pellegrini 6. The method reported by this group describes 
casting a commercial preparation of fibrin glue designed for haemostasis (Tissucol/Tissell, 
Baxter Healthcare) within a 3 cm diameter plastic ring 13,14. Presumably the plastic ring 
facilitates handling of the fibrin gel during cell culture and application to the ocular surface, 
although little reference is made to this in the literature.  
 
One of the more elaborate methods used to support biomaterials for RPE implants, developed 
by a team within the California Institute for Regenerative Medicine, has been to fabricate a 
material known as a Mesh Supported Parylene Membrane (MSPM) 65. Essentially, a mesh 
frame is formed using a multi-step approach that includes lithography, wet etching and the 
creation of circular holes. A sub-micron thick membrane of Parylene-C is then layered on top 
of this mesh support and used as a biomaterial membrane (after coating with Matrigel or 
vitronectin) for the culture of RPE cells. It is assumed that the MSPM is used as an anchored 
structure inside tissue culture plastic flasks that are flooded with culture medium 66.  
 
3.2. Commercially available options. While numerous patents have been written describing 
different cell culture systems, surprisingly few commercial products are readily available to 
researchers looking to mount their test biomaterials. Two widely available product ranges are 
Snapwell! cell culture inserts manufactured by Corning"/Costar", and CellCrown! cell 
culture inserts manufactured by Scaffdex (Tampere, Finland). Both products are distributed 
  
internationally by Sigma-Aldrich. Specific details for each product range including 
approximate prices are listed in Table 1. A third option developed by researchers from the 
University of Regensburg (Regensburg, Germany) and marketed as MINUSHEET is 
available as part of a more comprehensive cell culture system 67. A further commercial 
product for discussion has been specifically designed for the purpose of mounting and 
applying HAM to the ocular surface (e.g. ProKera/Bio-Tissue, Doral, FL, USA).  
 
Snapwell! culture inserts are essentially similar to standard cell culture inserts with the 
notable exception being that the insert base housing the porous membrane can be removed, 
thus facilitating tests of cell function in other devices (e.g. Ussing chamber). The added 
advantage of this design, however, is that test membranes, if sufficiently thin and strong, can 
be clamped between the upper and lower insert components. Theoretically, the porosity of the 
fitted membranes should enable adequate movement of both nutrients and culture products to 
facilitate co-culture experiments and measurements of growth factor secretion through the 
basal culture surface. CellCrown!cell culture inserts are likewise supplied with detachable 
bases thus enabling other membranes of choice to be mounted. The bases, resembling collars, 
can also be purchased without fitted membranes thus providing free access to the basal culture 
surface. A wider range of different insert sizes is also available compared to Snapwell! 
inserts, although the manufacturing of 48-well and 96-well format inserts will be discontinued 
from 2017.  
 
  
MINUSHEET is sold commercially by MINUCELL & MINUTISSUE Vertriebs GmbH 
(Germany) as part of a comprehensive cell culture system designed for in vitro studies of 
tissue engineering and pharmacological research. Numerous publications are based upon 
successful use of these products and a detailed discussion of the factors to consider in 
performing such work are provided in a freely available e-Book by Professor Will W. Minuth 
and Lucia Denk 67. The MINUSHEET (Part No. 1300) consists of a base ring designed to 
accommodate a 13 mm diameter membrane of choice and held in place with a tension ring. 
Both ring components can reportedly be sterilized using an autoclave, ethanol or 
formaldehyde. The assembled components are designed to fit within wells of a 12-well style 
cell culture plate, but can also be inserted into a variety of different perfusion chambers 
supplied by the same company.  
 
In the case of researchers already committed to using HAM, this material can be purchased 
from TissueTech Inc. (FL, USA) as a pre-mounted membrane clamped between two 
poly(methyl methacrylate) (PMMA) rings. While this product range (ProKera/Bio-Tissue, 
Doral, FL, USA) is specifically sold as a therapeutic bandage for the treatment of various 
ocular surface disorders, it may theoretically also be used as a substrate for the cultivation and 
implantation of cells. The mounting ring resembles that used for the prevention of 
symblepharon formation following trauma to the ocular surface. Standard symblepharon rings 
also have potential for mounting some biomaterials and especially those being designed for 






4. Innovative in-house designs 
 
4.1. Modified micro-Boyden chambers. In 1962 the Australian immunologist/ecologist 
Stephen Boyden published a technique for measuring the directed migration of leukocytes 
towards chemotactic factors 68. The apparatus as originally described by Boyden consisted of 
a porous polycarbonate membrane mounted between an upper and lower chamber constructed 
from Perspex. Over the years, numerous modifications have been made to this technique 
including those leading to the routine manufacture of porous membranes bonded to the 
bottom of cell culture well inserts. Nevertheless, an alternative modification of Boyden’s 
design, described by Australian pathologist Leon Bignold 69 (micro-Boyden chamber) has 
served as inspiration for one of our in-house designs for mounting experimental biomaterials 
(Figure 1).  
 
One of the key elements in Bignold’s micro-Boyden chamber design was to utilize 
components readily available in most laboratories and local hardware stores. As such the 
upper chamber (a flat O-ring cut from a sheet of silicon rubber) and lower chamber (Perspex 
disk with a central well drilled into it) were clamped together by being assembled within the 
upper ~2 cm end of a 15 mL polypropylene centrifuge tube and its screw-on lid, respectively. 
An additional plastic O-ring was placed between the upper chamber and porous polycarbonate 
membrane to reduce torsion on the membrane during chamber assembly. In doing so the goal 
was to create a watertight seal around the edges of the membrane so that any diffusion of 
  
lower chamber contents (a chemotactic factor in this case) would be restricted to the pores 
within the polycarbonate membrane (vital to creation of a consistent concentration gradient). 
Incorporating these ideas, we designed an upper ring-shaped chamber component to 
accommodate a recessed silicone rubber O-ring and to directly thread into a lower ring-shaped 
base chamber component (Figure 1). Both chamber components are constructed from poly-
tetra-fluoro-ethylene (PTFE, Teflon#) to support sterilization by use of autoclave or 
treatment with 70% ethanol. A central hole within upper and lower chamber components, 
combined with the relatively low height profile, supports routine monitoring of cultures by 
phase contrast microscopy when growing on either the upper or lower surface of assembled 
membranes. In the original design for this chamber, four channels were cut into the surface of 
each chamber component in an effort to facilitate the movement of growth medium. The 
channel within the upper chamber also provided a purchase point for tightening of the 
chamber using forceps. In our latest design, however, this concept has been developed further 
by essentially widening the channels to the point of leaving four small feet (castellations) and 
by beveling the inner chamber edges. The upper castellation points, as for grooves used in the 
initial design, provide a purchase point for tightening of the chamber using forceps. 
 
4.1.1. Application to corneal epithelial cells. Our modified micro-Boyden chamber 
was originally designed for the purpose of preliminary testing of biomaterials for corneal 
epithelial cells 18. In particular, we have successfully used HAM and transparent membranes 
constructed from silk fibroin. The procedure for mounting HAM is as follows. Following 
removal of residual amniotic epithelial cells, the nitrocellulose backing paper is removed and 
the HAM flattened as best as possible in a dry sterile Petri dish (60 mm diameter or greater). 
  
A silicone O-ring is then placed underneath the membrane. The upper chamber component is 
then pressed down onto the O-ring until the HAM becomes clamped in place. The 
surrounding HAM is subsequently trimmed to a distance of approximately 5 mm away from 
the edge of the O-ring. Finally, the upper chamber fitted with HAM is then gently screwed 
down into the lower chamber compartment until finger tight. A similar strategy has been used 
for fibroin membranes although these are typically mounted when dry with the O-ring being 
placed on top. Once assembled, the dry fibroin membranes can be stored in sterile 50 mL 
centrifuge tubes and we have successfully shipped them to collaborators across the world. 
While the inner, smaller chamber is designed to be the upper chamber, the entire apparatus 
can be inverted to allow seeding of cells onto either surface. Using this approach we have 
successfully produced co-cultures of corneal epithelial cells and corneal stromal cells 
separated by fibroin-based scaffolds 70. A final advantage of this design is that since all 
components are compatible with formalin, ethanol and xylene, the entire culture can be fixed 
and processed into paraffin in preparation for histology. As such, the chamber does not 
require disassembly until the cultures/membranes are ready for embedding.  
 
4.1.2. Application to corneal endothelial cells. We routinely grow corneal endothelial 
cells on silk fibroin membranes that have been coated with collagen type IV. Collagen coating 
is achieved by pipetting a solution of collagen type IV onto one side of the dry silk fibroin 
membrane that has been placed within our modified micro-Boyden chamber. The whole 
assembly is then dried overnight at 40 °C under a vacuum of -70 kPa. The coated membrane 
within the modified micro-Boyden chamber can then be used for cell culture once it has been 
sterilized with 70% ethanol and washed with PBS. Corneal endothelial cells form monolayers 
  
that can be easily examined using phase contrast microscopy during growth on these 
suspended membranes. Once a complete monolayer has formed, the cell constructs can be 
removed from the modified micro-Boyden chamber to undergo functional testing in an Ussing 
chamber.  
 
4.1.3. Application to retinal pigment epithelial cells. We have successfully used our 
modified micro-Boyden chamber with membranes made from silk fibroin (3 !m thickness) to 
grow and study RPE cells 71,72. The modified chamber design facilitates proper cell culture 
conditions for this cell type, maintaining independent volumes of culture medium on either 
side of the membrane over extended culture period (>4 months has been tested). This culture 
set up allows development of appropriate polarization and maturation of the RPE culture. Co-
cultures of RPE cells and choroidal vascular endothelial cells can be established by sequential 
seeding of cells onto either side of the chamber 73. Moreover this design enables ongoing 
functional testing to be performed during extended culture time. The apical and basal volumes 
of culture medium can be collected separately and examined for differences in growth factor 
concentration via immunoassay. Our chamber also supports use of the EVOM2 
Voltohmmeter (World Precision Instruments) using the chopstick electrode set (STX3) 
allowing routine measurement of a developing trans-epithelial resistance by the RPE cultures 
73. In combination with non-invasive monitoring (i.e. phase contrast microscopy), these 
functional assays inform readiness of the cultures for further experimentation. As for corneal 
cells, the modified micro-Boyden-chambers also provide a convenient protective holder 
during fixation and storage of the cultures prior to subsequent examination by 




4.2. The “Ludowici” chamber. The inspiration for this second chamber design arose from our 
desire to translate our in vitro studies of corneal epithelial cells to clinical trials. More 
specifically, we required a chamber design that would accommodate larger sheets of 
membranes as required for application to the ocular surface of patients and large animal 
models (e.g. sheep and rabbits). The initial thought was simply to make a larger version of the 
modified micro-Boyden chambers. Nevertheless, a screw thread mechanism of clamping was 
considered to produce insufficient tension and promote rippling of the membrane surface. 
Discussion of alternative options with a local manufacturer (Ludowici Sealing Solutions) led 
to design of double PTFE ring assembly that could be clamped together via use of an internal 
flange (within top ring) and matching gutter (in base ring) (Figure 2). A series of 
castellations/feet were again used to encourage flow of culture medium when the entire 
chamber is laid flat in either orientation. Additionally, four small holes were placed through 
the base ring in order to assist with chamber disassembly. In theory disassembly would be 
enabled through downward pressure against an aluminium block fitted with four small metal 
pins to match the position of holes located in the base ring. In practice, however, we have 
been able to routinely dislodge the inner/upper ring by twisting the entire apparatus until a 
small section becomes unlocked. We have successfully used this device for mounting either 
HAM or fibroin membranes. The critical steps involved with mounting of HAM are displayed 
in Figure 2. Once thawed and washed in sterile buffer, the entire sheet of HAM is placed on 
top of the lower ring such that approximately 5 mm resides outside the inner gutter. The top 
ring is then placed on top and downward pressure applied by hand until the upper flange 
  
snaps into place within the gutter. In order to maintain sterility during this procedure, the 
entire apparatus is placed within a sterile Petri dish as demonstrated in Figure 2C. Once 
mounted, and with the aid of a dissecting microscope, the backing paper is gently punctured 
with watchmaker forceps and pealed away in sections until the central field is entirely clear. 
The HAM can then be processed to remove remnants of amniotic epithelium by treatment of 
choice. In our case, we have used treatment for 5-10 minutes with 0.05% trypsin with 1 mM 
EDTA. Vigorous pipetting of solution across the HAM surface is preferred to mechanical 
scraping. Given that the HAM is held taut and without backing paper, the extent of epithelial 
debridement can be effectively monitored by phase contrast microscopy and repeated as often 
as necessary. Since fibroin membrane has less elasticity than HAM, we have found it 
necessary to initially overfill the membrane by indenting the centre, which then subsequently 
becomes flat and taut as the two rings are snapped together. As for the smaller chambers, cells 
can be co-cultured on either side of the mounted membrane simply by inverting the apparatus 
to the desired side when seeding. On day of surgery, the entire chamber is transported in a 
sterile specimen container while immersed in culture medium. The chamber is then simply 
lowered into position across the ocular surface in the desired orientation. Application in 
rabbits is further facilitated by proptosing the eye prior to surgery (Figure 2E). Once again the 
entire chamber can be processed into paraffin without disassembly.  
 
4.3. The Dunphy chamber. As with the other designs, the idea here was to create a flat surface 
for the in vitro culture of ocular cells (Figure 3). The initial motivation came from difficulties 
encountered with commercially available systems for membranes such as Scaffdex!. 
Commercially available systems tended to tear fragile membranes prepared from electrospun 
  
fibers, often required some form of manipulation to render them suitable for bespoke 
applications, and offered little scope for co-culture experiments. Furthermore, they are not re-
usable making them a rather costly option. While the Dunphy chamber was originally 
designed for use with electrospun nanofibre scaffolds prepared from polyesters including 
poly(lactic-co-glycolic acid) (PLGA), it can also be used with other membranous scaffolds 
including HAM.  
 
The initial design fits snugly into a 24-well plate leaving a small space between the well and 
chamber to accommodate media changes using a pipette. The entire culture area is 
approximately 0.5 cm2, a suitable size for a corneal graft however the design could easily be 
scaled up to increase the culture area. Like the Ludowici chamber, the Dunphy chamber 
consists of two separate pieces clamped together: a biocompatible PTFE base and stainless 
steel retaining clip. To mount a membrane, circular discs of the biomaterial are first cut 
slightly larger than the diameter of the chamber, e.g., using a 12 mm biopsy punch. The semi-
flexible metallic clip is open at one end allowing it to be stretched with forceps and then 
placed around the membrane, which is clamped around the upper lip of the PTFE base. Once 
the clip is released, it snaps firmly into place to secure the membrane. Similar to a drum or 
embroidery ring, the membrane is gripped in tension as shown in Figure 3B to D. Additional 
groove features were added to the base to allow medium to flow under the chamber and small 
“legs” were included on the “top-side” of the PTFE to enable the chamber to stand stably 
when inverted. This facilitates cell seeding on both sides of a single membrane or bi-layered 
scaffold. Dimensions were chosen such that medium can flow under the chamber when 
upright or inverted to allow nutrients and oxygen to reach the cells, while maintaining the 
  
minimum dimensional requirements such that culture medium could be used economically. In 
our experiments, we successfully used the chamber to co-culture corneal epithelial and 
stromal cells on opposite sides of a bi-layered membrane to mimic the native structure of the 
anterior cornea.  
 
The idea behind the clamp-style mechanism is to prevent twisting, which can cause the 
membrane to break during the mounting process and may affect stresses across the membrane 
surface. Furthermore, the design has off-the-shelf potential; the entire system, including the 
membrane, can be sterilized and packaged for laboratory or clinical use, such that the user can 
simply choose a membrane size and type, place it into an appropriately sized culture plate 
with medium, and subsequently seed with the chosen cell type. This helps to avoid 
contamination issues often associated with manipulating biomaterials for use, both 
experimentally and clinically. In our hands, the membranes were mounted first and then 
sterilized by soaking the entire system in ethanol or by exposure to ultraviolet (UV) 
irradiation. Following a predetermined culture period, the membranes were easily dismounted 
by loosening the retaining ring with sterile forceps to release the membrane. The membrane 
can then be cut to suitable dimensions using a trephine or biopsy punch. Finally, the chamber 
can be sterilized for re-use; achieved by immersion in ethanol, ethylene oxide sterilization, or 
autoclaving, although, the latter should be used with caution as the heating process can cause 
leaching from some polymeric materials to occur and may affect cell viability. 
 
4.4. The Zakaria chamber (Amnion ring). Once again the idea was to develop a fixation 
device for HAM that would immobilize this material during limbal epithelial stem cell 
  
culture, transportation and surgical transplantation 74,75(Figure 4). The diameter of the ring is 
larger than both the modified micro-Boyden Chamber and the Dunphy chamber, requiring 
culture to be performed in a 60 mm Petri dish. The HAM is oriented epithelial side down, on 
the bottom of a culture dish. The inner ring is centered over the HAM and its edges pulled 
over the lip of the ring. The inner ring with membrane are grasped with forceps and flipped 
over. The outer ring is then positioned over the HAM and pressure applied to click the rings 
in place. The rings create a taut drum-like appearance of the membrane and are placed 
membrane surface face-down in culture. A limbal biopsy is placed at the center of the HAM 
and cultured at the air liquid interface. The design of the Zakaria chamber results in a 
separation of 1.6 to 2.1 mm between the membrane and the bottom of the culture dish to 
ensure a reservoir of medium for nutrient exchange. The basic mechanism here is similar to 
the other designs described previously, incorporating the idea of an embroidery drum to 
maintain immobility of the contained membrane. The advantage of this system is that once 
the rings have ‘clicked’ together, the HAM is contained and cannot slip out or become 
detached. This ensures an anchored membrane during culture and transportation to the 
operating room. A 33.2 mm diameter size for the ring was chosen to not only ensure adequate 
surface area for outgrowth of the limbal epithelial cells, but to also aid in the transplantation 
procedure itself. Following corneal pannus dissection, the surgeon can apply fibrin glue to the 
surface of the cornea, position the graft over it and trephine out the required graft size without 
manipulating the graft in any way. The ‘no-touch’ surgical technique helps maintain viability 
of transplanted cells. The remainder of the graft is embedded in paraffin and stored as a 







Membranes are a popular choice of scaffold for ophthalmic cell therapies and also support 
studies of ocular cell function in vitro. Ideally, the choice of membrane mounting technique 
should support a flat surface with adequate tension to facilitate optimal cell attachment and 
growth. In some cases (e.g. for RPE cells) it is advantageous to create separate upper and 
lower membrane compartments for studies of polarized cell function (e.g. barrier function or 
growth factor secretion). While a small number of mounting devices are available 
commercially (e.g. Snapwell# and CellCrown#), the limitations associated with these 
products (including size range, sealing properties and incompatibility with standard tissue 
processing techniques) have prompted the development of several in-house designs. Table 3 
demonstrates the varying suitability of our chamber designs according to required application. 
The ability to directly monitor cultures by phase contrast microscopy while mounted within 
these chambers is highly desirable (Figure 5). The modified micro-Boyden chamber and 
Dunphy chamber are best suited to in vitro studies of cell function on bespoke membranes of 
choice. In contrast, the Ludowici chamber and Zakaria chamber (amnion ring) support 
handling of larger membranes during cell culture and subsequent application to the ocular 
surface. As an added advantage, all of these designs are made from materials (e.g. PTFE or 
PEEK) that are readily amenable to sterilization (a regulatory requirement for clinical 
manufacturing) and are compatible with standard tissue processing methods into paraffin 
blocks (thus facilitating quality assurance tests on final product). In achieving these 
  
requirements, we recommend our chamber designs to others working within the field of 
ophthalmology as well as those working with other epithelial cells of clinical significance. For 
example, we consider that our chamber designs may well assist the development of tissue for 
repairing portions of the respiratory tract (e.g. trachea), the gastrointestinal tract (e.g. 
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Cell culture inserts with 
removable collar containing 
a porous (0.4 µm) 
membrane composed of 
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3407 (PC: 24 well/24) 
3801 (PE: 24 well/24) 
 
CLS3407 (PC: 24 well/24) 








Cell culture inserts with 
removable collar for 
securing materials of 
choice. Collars also 
available with pre-attached 








C00003S (6 well/3) 
C00002S (12 well/6) 
C00001S (24 well/12) 
C00004S (48 well/6x4)** 
C00005S (96 well/8x6)** 
Z681806 (6 well/3) 
Z681849 (12 well/6) 
Z681903 (24 well/12) 
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Cryo-preserved amniotic 
membrane clamped 










Notes: PMMA = poly(methyl methacrylate), PC = polycarbonate, PE = polyester, *Prices 
exclude delivery charges and refer to sterile product option where available. All prices are 
subject to change. **Manufacturing to cease in 2017. 
  
Table 2. Materials and components used for in-house designs 




CNC Components Pty. Ltd. 
(Geebung, QLD, Australia) 
 
Ludowici Sealing Solutions 
(Brendale, QLD, Australia)  
Upper ring: QUT-0002-0006  
Base ring: QUT-0002-0007 
Both made from PTFE 
Silicone rubber O-ring: 
RSB012 








Ludowici Sealing Solutions 
(Brendale, QLD, Australia) 
 
Upper ring: L140841 
Base ring: L140840 







Medical Engineering Unit 
(Queens Medical Centre, 
Nottingham, UK) 
Per set (non-sterile) 
PTFE base 
Stainless steel retaining clip 






O&O Medical Device 
Consultants (Frascati, 
Rome, Italy) 
Per pair/Sterile & Packed:  
Lower: Ø36,8*Ø33,2*LG6  
Upper: Ø35,6*Ø31,3*LG6,5 




Notes: PTFE = poly-tetra-fluoro-ethylene (Teflon#), PEEK = poly-ether-ether-ketone 
(Ketron#). *All prices are subject to change. 
  
Table 3. Quick reference chamber guide according to required application. 
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Cell types tested: 
• Corneal/limbal epithelium 
• Corneal stroma 
• Corneal endothelium 



















• Amniotic membrane 
• Fibroin membrane 
• Collagen membrane 






















Medical device for applying 














Notes: TER = trans-epithelial resistance; RPE = retinal pigment epithelium.  
*”Not ideal” due to the relatively shallow and larger width of chamber compartments. 
**Numerous sources of RPE cells have been successfully used including ARPE-19 cells, RPE 




Figure 1. The modified micro-Boyden chamber. (A) Schematic displaying the micro-
Boyden chamber design in cross-section and following assembly. The silicone O-ring is 
shown in red. (B) Appearance of upper and lower chamber prior to assembly. The silicone O-
ring can be seen fitted within the upturned upper chamber. (C) Tightening of chamber 
components by threading together. The upper castellations provide a leverage point for 
tightening with forceps. (D) Example of chamber use in conjunction with experimental silk 




Figure 2. The Ludowici Chamber. (A) Schematic of Ludowici chamber design in cross-
section. (B) Sheet of donor human amniotic membrane (HAM) after being thawed and 
washed in culture medium. (C) Assembly of HAM into Ludowici chamber by application of 
pressure through base and lid of sterile Petri dish. (D) Appearance of HAM following 
mounting into chamber. The backing paper is subsequently peeled away prior to further 
preparation. (E) Application of limbal epithelial cell culture grown on HAM onto the surface 







Figure 3. The Dunphy chamber. (A) Schematic displaying the Dunphy chamber 
components consisting of PTFE base (illustrated in blue) and a stainless steel retaining clip 
(illustrated in red) (B) Appearance of assembled chamber containing a synthetic electrospun 
polymer membrane (PLGA) when viewed from above (C) Appearance of assembled chamber 
containing membrane when viewed from below (D) Example of chamber use with 24-well 
culture plate. 
 
Figure 4. The Zakaria chamber (Amnion ring). (A to C) Schematic drawings displaying 
the upper and lower ring components when separate and combined. Distance measurements 
are displayed in millimeters (D to F) Photographs of ring components when displayed 
separately and combined. Prior to assembly, a sheet of amniotic membrane (not shown) is 
draped across the lower ring component. (G to I) Photographs illustrating the ‘no-touch’ 
transplantation technique for limbal epithelium cultured on human amniotic membrane 
(HAM). (G) A drop of fibrin glue is placed onto the corneal surface and the HAM positioned 
over it. (H) Gentle downward pressure is applied sealing the surfaces together. (I) A trephine 








Figure 5. Examples of culture visibility and growth achieved using each chamber design.  
(A) The human RPE cell line ARPE-19 after 2 months growth on a collagen coated fibroin 
membrane, while mounted within the modified micro-Boyden chamber (phase contrast 
optics). (B) Rabbit limbal mesenchymal stromal cells after 4 days growth on a sheet of 
denuded HAM, while mounted within the Ludowici chamber (phase contrast optics). (C) 
SV40-immortalised human corneal epithelial cells stained with phalloidin after 2 weeks 
growth on a nanofibrous PLGA scaffold, while mounted within the Dunphy chamber 
(confocal fluorescence microscopy is used owing to the poor transparency of the scaffold). 
(D) Human limbal epithelial cells after 14 days outgrowth from a tissue biopsy attached to 
denuded HAM, while mounted within the Zakaria chamber (phase contrast optics). The 
approximate scale for Parts A and B is displayed in B (200 !m bar). The approximate scale 
for Parts C and D is displayed in D (100 !m bar).  





